AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Businesswire

Published November 4, 2026

Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study

Read the full story at Businesswire

hallucinogenic psychedelic . The study evaluated EB-003 in mice using ... This press release contains forward-looking statements and forward.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelic press release